Member Info for flyingmachine

scart, I am very comfortable that this is all above board. In my email to LHGP I never mentioned Genedrive at all, it was the co-CEO of LHGP that actually mentioned Genedrive in his response.

PP, in reply to your query about TR1 (or lack of) mystery today. From my own understanding I was fully expecting a couple of TR1s today related to River &Mercantile, and Odey Asset Mngt but they didn't arrive and I have no idea why, since both holdings have dropped below 3% threshold. There may be something obscure within the FCA rule book but perhaps we may see them tomorrow?

I emailed Lions Head Global Partners earlier today and asked confirmation they were in partnership with DIVOC in India. This is the reply from Christopher Egerton-Warburton, co-CEO of LHGP....

"yes this is group we are associated with to bring the Genedrive test to India".

So great news and confirmation that India will be one of the key markets for the GDR Covid test.

Yes, I agree, web page archive from the 29th May was likely taken before the RNS announced on the 29th am, makes sense. So a good indication Calculus have stopped selling since that date.

Yes, so should see 3 TR1s for Calculus, River & Mercantile and Odey Asset Management on Monday, then hopefully brakes are fully off.

I don't recall a Holdings RNS for last 600k sell from Calculus, so may see a TR1 on Monday as that crossed a % boundary, or am I wrong to expect that?.

....should have added - shares in issue from 28th May onwards is 44,870,071. Previous to that date it was 34,870,071.

jack_allis, here are the previous ii significant shareholdings (not including Directors), going backwards in time from today to early May :

6th June :
Substantial holdings Shares held %
Calculus Capital 4,669,282 10.41%*
BGF Investment Management Limited 3,506,770 7.815% *
Spreadex Ltd 1,927,502 5.9%**
Mr Hugh JJ Rylands 1,686,603 3.73%

29th May:
Substantial holdings Shares held %
Calculus Capital 5,269,282 11.74%*
BGF Investment Management Limited 3,506,770 7.815% *
River & Mercantile Asset Management 1,819,957 4.06% *
Spreadex Ltd 1,627,283 3.63%**
Mr Hugh JJ Rylands 1,494,246 3.33%
Odey Asset Mgt LLP 1,434,578 3.20%

24th May:
Substantial holdings Shares held %
Calculus Capital 5,869,282 16.83%*
BGF Investment Management Limited 2,594,270 7.44% *
HSBC Bank plc 1,917,362 5.498%
River & Mercantile Asset Management 1,819,957 5.4% *
Spreadex Ltd 1,627,283 4.67%**
Mr Hugh JJ Rylands 1,494,246 4.29%
Odey Asset Mgt LLP 1,434,578 4.11%

13th May:
Substantial holdings Shares held %
Calculus Capital 5,869,282 16.83%*
BGF Investment Management Limited 4,347,826 12.8% *
River & Mercantile Asset Management 1,819,957 5.4% *
Spreadex Ltd 1,627,283 4.67%**
Mr Hugh JJ Rylands 1,494,246 4.29%
Odey Asset Mgt LLP 1,434,578 4.11%

11th May:
Substantial holdings Shares held %
Calculus Capital 6,588,032 18.9%*
BGF Investment Management Limited 4,347,826 12.8% *
River & Mercantile Asset Management 1,819,957 5.4% *
Spreadex Ltd 1,627,283 4.67%**
Mr Hugh JJ Rylands 1,494,246 4.29%
Odey Asset Mgt LLP 1,434,578 4.11%

Stanman, it is an interesting question that I have also pondered over recently. For me, it is preferable for collection to be taken by swabbing inside of the mouth and/or placing in the mouth for a short period of time (as in the video), rather than someone spitting/spilling saliva into a small pot on the device, or a collection pot which you pour onto the device. Spitting or spilling saliva onto the device from your mouth is not condusive to a safe testing environment, which is important for populous areas like airports and other busy meeting points. Collection from within the mouth is preferable but the demo video spent about 5 mins going through what to do and what not to do so really not as simple as one would think at first thought and room for user error. Also, the test for alcohol and drugs probably require less sensitivity than for particles of a virus. So it will be interesting to see what they come up with in order to collect enough viral capture.

Thankyou dogdays, we all appreciate that.

Ok, I've sent an email to the DM 'story tips' section to follow up their great article on swab testing issues by taking a look at a new CE Marked PCR test that has buit-in integrated controls that help mitigate and provide better understanding of these current issues.

Is anyone able to email Sam Blanchard, the Daily Mail reporter, with the Linked-In post and suggest he interview David Budd about the USP of Genedrive's CE Marked PCR test?

Myles, the placing was a shock, but logical. I believe AS is a smart CEO andappreciates that there is still potential for the POC Covid test to fall flatter than people expect because since it is an antigen test, it will not be sensitive enough in clinical settings (a limitation of antigen testing) so would simply become a pre-screening test before a more accurate PCR test is taken. This is even the use case description in the investor literature (May 22nd) of their closest competitor, Sona Nantech, who are already in POC test validation. AS hedged his bets - raise the money from placing now to fully fund the precision cancer treatment trials to completion before the final results of the POC test development and validation come out, since could be not so good as everyone has been lead to believe.

I think the timing of AVCT's placing is down to the CEOs appreciation that there is still potential for their massively hyped-up POC Covid test to fall flat because since it is an antigen test, it will not be sensitive enough (a limitation of antigen testing) so would simply be a pre-screening test before a more accurate PCR test is taken. This is even the use case description in the investor literature (May 22nd) of their closest competitor, Sona Nantech, who are already in POC test validation. AS hedged his bets - raise the money from placing now to fully fund their precision cancer treatment trials to completion ( a couple of years), before the final results of their POC test development and validation which are still a roll of the dice.

In case anyone else was wondering, I asked the question why Distributors have not yet visibly displayed details of the new GDR PCR test. This is the response from the PR company.....

"Firstly, it's only been 10 working days since the Company received CE-IVD mark for the product, but also major distributors like Sysmex don't begin full marketing of new products on their website immediately as they usually undertake customer referrals / evaluations first and this is what they are doing at the moment."

Understandable then, just process, just a little more patience needed.....but I do expect the product to start flying off the shelves once customer evaluations are complete.

Although both high sensitivity and specificity are important for Covid PCR tests, it is the sensitivity of the test that is most key since as it is the parameter that determines the number of false negatives. A false negative is not good since it means the test could indicate that someone does not have the active virus, when in fact they do, then they subsequently go about the community inadvertently spreading the Covid disease.

In the GDR RNS on the 22nd May, GDR stated that the sensitivity of their test was 100%, meaning there was very little risk of any false negative from the test. Comparing this against the sensitivity of the PrimerDesign/Novacyt PCR test used by PHE, that has a sensitivity of 98% (according to PrimerDesign CE Mark document), so there is a greater risk of false negatives particularly when preparation of reagents (not necessary with GDR test) can cause errors in testing. So that test falls short of the sensitivity performance of the GDR PCR test (100%).

This level of sensitivity in the GDR test, alongside its other unique features - simplicity, consistency and efficiency means it stands out against other PCR tests with the best performance and reliability.. My conclusion, it will sell well.

shortter, you have incorrect information. BBI Solutions is part of the RTC....

"The UK-RTC, which was announced by the UK Government yesterday, comprises Omega, Abingdon Health Limited, BBI Solutions Limited, CIGA Healthcare Limited, and the University of Oxford (the "Parties") and was formed at the request of the UK Government to support the development and manufacturing scale-up of a COVID-19 lateral flow antibody test ("COVID-19 Rapid Test") to determine whether people have developed immunity after contracting the virus."

FDA EUA approval for PCR test
First sales and contracts for CE Marked and approved PCR test
Development of POC test on schedule
£66m Mcap today blown away
....and unfortunately R rate > 1 in many parts of the world

...and request made to David Budd...."Hello David, your solution has been reviewed. The review would like to know if you could provide details on validation for COVID-19 please".

So no doubt the Genedrive development team will now be fully focussed on this POC assay, having completed their development of the CE marked PCR test.

Genedrive POC mobile device is marked as 'one to watch' by Department of Health and Social Care 'Testing challenge' for Desktop PCR and POC testing.....

https://testingmethods.crowdicity.com/post/3167180

Another bonus on top of the current GDR PCR test....